United States · Health Care startup
United States · ImmunityBio
ImmunityBio is a late-stage immunotherapy startup that is developing treatments to drive immunogenic pathways in the fight against cancer.
Funding reportedLast round: Post ipo debt
What company datasets say ImmunityBio raised
Funding, as reported
Reported in all$1.1Bin dollars
Rounds13
Last roundPost ipo debt
Last round dateJan 2024
Investors listed3
Founders and team
From ImmunityBio's own website and the SEC filings it signed: 9 on the team.
- Rich AdcockPresident & Chief Executive Officer
- Elizabeth GabitzschSenior Vice President, Product Development & Vaccine Programs
- Emily ArisonSenior Vice President of Human Resources
- Matthew HilmanVice President US Commercial – Urologic Oncology
- Sarah SingletonChief Communications Officer & Head of Patient Advocacy
- Regan LauerChief Accounting Officer
- David SachsChief Financial Officer
- Dr. Patrick Soon-ShiongExecutive Chairman and Global Chief
- Richard AdcockExecutive Officer, Directori
On the board, as filediBarry SimonCheryl CohenChristobel SeleckyJohn BrennanLinda MaxwellMichael BlaszykWesley Clark
On 2 portfolio pages
Investors who name them
Each firm lists ImmunityBio on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.
Health Care in United States
Startups like it
Is this your company?
Add your raise, your deck and your story, and put ImmunityBio in front of investors. Or tell us what we have wrong.